Physician profile
Matthew E Dickson
NPI 1588806749
$7,117.32
in general payments reported to CMS, 2019-2025
33 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $541 · 2021: $731 · 2022: $1,272 · 2023: $1,283 · 2024: $1,327 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681 · Debt Forgiveness: $55.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.55 |
| Debt Forgiveness | $55.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $837.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $713.14 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Novartis Pharmaceuticals Corporation | $645.66 | 2019-2025 | |
| Esperion Therapeutics, INC. | $539.86 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $497.18 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $495.76 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $426.83 | 2019-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $403.50 | 2019-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.37 | 2022-2025 | Jardiance |
| Amgen INC. | $303.09 | 2020-2025 | Repatha |
| Boston Scientific Corporation | $258.72 | 2022-2025 | Watchman Flx, Watchman Access System, Wavewriter Alpha Prime 16 |
| Heartflow, INC. | $215.27 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $200.34 | 2019-2024 | Farxiga, Tezspire |
| Kiniksa Pharmaceuticals, Ltd. | $180.80 | 2021-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $116.87 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $110.07 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $104.01 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $96.97 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $91.75 | 2023-2025 | |
| Amarin Pharma, INC. | $81.70 | 2019-2021 | |
| Scpharmaceuticals INC. | $67.42 | 2024-2025 | |
| Astellas Pharma US INC | $50.46 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $49.51 | 2019-2023 | |
| Philips North America LLC | $49.12 | 2020-2023 | |
| Inspire Medical Systems, INC. | $46.73 | 2024-2025 | Inspire |
| Bardy Diagnostics, INC. | $41.00 | 2019 | |
| Cvrx, INC. | $37.79 | 2024 | Barostim Neo System |
| Medtronic, INC. | $32.17 | 2021-2022 | |
| Lilly USA, LLC | $30.76 | 2024 | Mounjaro, Zepbound |
| Arbor Pharmaceuticals, INC. | $25.63 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $22.93 | 2024-2025 | Rhythm Express, Rhythm Express |
| Novo Nordisk INC | $18.07 | 2023 | Ozempic, Rybelsus |
| United Therapeutics Corporation | $16.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.